IBOV 204,626.74 ▲ 0.15% IPSA 10,944.69 ▼ 0.25% IPC MEX 67,663.29 ▲ 1.31% MERVAL 2,848,932 ▼ 0.35% COLCAP 2,577.69 ▼ 0.11% BVL PERÚ 60,210.69 ▼ 0.11% USD/BRL5.07▼ 0.46% USD/MXN18.50▲ 0.47% USD/CLP984.40▲ 0.32% USD/COP3,163▼ 1.02% USD/PEN3.44▼ 0.01% USD/ARS1,518▲ 0.30% USD/UYU40.13▲ 3.08% USD/PYG5,686▲ 3.07% USD/BOB11.61▲ 2.27% USD/DOP61.26▲ 0.43% USD/CRC448.47▲ 1.59% USD/GTQ7.65▲ 3.30% USD/HNL26.86▲ 0.34% USD/NIO36.62▼ 0.07% USD/VES877.92▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.73▲ 2.13% EUR/BRL5.70▲ 1.06% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 204,626.74 ▲ 0.15% IPSA 10,944.69 ▼ 0.25% IPC MEX 67,663.29 ▲ 1.31% MERVAL 2,848,932 ▼ 0.35% COLCAP 2,577.69 ▼ 0.11% BVL PERÚ 60,210.69 ▼ 0.11% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Friday, October 16, 2026

The Next Wave of RNA Vaccines: Assessing Potential and Caution

By · November 30, 2023 · 2 min read

SaRNA vaccines mark a significant advancement in vaccine technology, evolving from conventional mRNA approaches.

These vaccines are designed to offer stronger immunity using smaller doses, aligning with the latest developments in vaccine science.

Unlike traditional mRNA vaccines, saRNA vaccines feature a unique self-replication mechanism.

This characteristic could potentially enhance their effectiveness, making them a notable innovation in vaccine development.

Companies like BioNTech and Arcturus Therapeutics are leading in this area, emphasizing the growing global interest in saRNA technologies.

The Next Wave of RNA Vaccines: Assessing Potential and Caution.
The Next Wave of RNA Vaccines: Assessing Potential and Caution.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Despite this progress, some aspects of saRNA vaccines have sparked speculation and concern.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “IMF sees Brazil as 8th-largest economy by 2027”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Among these are fears that saRNA might lead to cellular exhaustion and immune tolerance, although these claims require more empirical evidence and thorough clinical trials for validation.

The categorization of saRNA vaccines has also been a topic of debate. While they involve genetic material, they are generally classified as vaccines, not gene therapy products.

This distinction is crucial considering the complex regulatory, scientific, and ethical implications.

Understanding the long-term effects of saRNA vaccines is an area of ongoing investigation.

Conducting comprehensive long-term studies and continuous monitoring is essential to assess their safety and efficacy fully.

The speculative nature of potential long-term impacts calls for a cautious and informed approach to their use.

In conclusion, the development of saRNA vaccines represents a significant step in RNA-based vaccine technology.

They promise enhanced effectiveness and the potential for reduced dosage frequency.

However, it is essential to approach these vaccines with a balanced view, recognizing both their scientifically established benefits and the areas that need further research.

As the field of saRNA vaccines progresses, continuous scientific research and peer-reviewed studies are essential.

They will clarify the actual effects of these vaccines, guaranteeing their effectiveness and ethical development.

This article was drafted with automated assistance and reviewed before publication. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief

Read More from The Rio Times

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.